Trek Financial LLC Buys 143,667 Shares of TransMedics Group, Inc. $TMDX

Posted by George Bondi on Nov 2nd, 2026

Trek Financial LLC bought a new position in TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm bought 143,667 shares of the company’s stock, valued at approximately $11,989,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Braidwell LP raised its holdings in shares of TransMedics Group by 85.1% during the 2nd quarter. Braidwell LP now owns 609,715 shares of the company’s stock worth $40,497,000 after acquiring an additional 280,324 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of TransMedics Group by 5.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 516,679 shares of the company’s stock valued at $51,355,000 after acquiring an additional 26,969 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of TransMedics Group by 6.1% in the second quarter. Wellington Management Group LLP now owns 515,973 shares of the company’s stock valued at $34,271,000 after purchasing an additional 29,500 shares during the period. Congress Asset Management Co. grew its holdings in shares of TransMedics Group by 11.0% in the third quarter. Congress Asset Management Co. now owns 252,952 shares of the company’s stock valued at $21,109,000 after purchasing an additional 25,118 shares during the period. Finally, Principal Financial Group Inc. increased its position in TransMedics Group by 19.4% during the first quarter. Principal Financial Group Inc. now owns 231,433 shares of the company’s stock worth $23,007,000 after purchasing an additional 37,656 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $65.99 on Monday. TransMedics Group, Inc. has a 52 week low of $60.10 and a 52 week high of $156.00. The business’s fifty day simple moving average is $81.65 and its 200-day simple moving average is $94.92. The firm has a market cap of $2.28 billion, a PE ratio of 16.96, a price-to-earnings-growth ratio of 0.91 and a beta of 2.14. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62.

TransMedics Group (NASDAQ:TMDX – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). The business had revenue of $189.95 million for the quarter, compared to analysts’ expectations of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%. The business’s revenue for the quarter was up 20.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.92 earnings per share. Equities analysts forecast that TransMedics Group, Inc. will post 1.46 earnings per share for the current year.

Insider Buying and Selling

In related news, Director David Weill bought 1,336 shares of the firm’s stock in a transaction on Friday, September 11th. The shares were bought at an average price of $81.63 per share, with a total value of $109,057.68. Following the completion of the transaction, the director directly owned 16,392 shares of the company’s stock, valued at $1,338,078.96. This represents a 8.87% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

TMDX has been the topic of a number of analyst reports. Canaccord Genuity Group reduced their target price on shares of TransMedics Group from $95.00 to $94.00 and set a “buy” rating on the stock in a research note on Tuesday, October 13th. Weiss Ratings raised shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Zacks Research cut shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. Needham & Company LLC restated a “buy” rating on shares of TransMedics Group in a report on Friday, September 11th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $100.00 price target (down from $120.00) on shares of TransMedics Group in a research report on Wednesday, August 5th. Five analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $115.60.

Check Out Our Latest Analysis on TMDX

TransMedics Group Company Profile

(Free Report)

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company’s primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.